GlassScriptPhysician profile
Kenneth D Varian
NPI 1578882817
$169,768.76
in general payments reported to CMS, 2019-2025
23 companies · $29K in 2025
The $29K reported for 2025 was more than what 87% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $30K · 2021: $54K · 2022: $9,736 · 2023: $32K · 2024: $13K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Travel and Lodging: $3,586 · Food and Beverage: $2,679 · Consulting Fee: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,350.00 |
| Travel and Lodging | $3,586.11 |
| Food and Beverage | $2,678.76 |
| Consulting Fee | $1,990.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80,271.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $63,176.63 | 2020-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21,526.00 | 2020-2023 | Jardiance |
| Lilly USA, LLC | $1,687.50 | 2020-2021 | |
| Abbott Laboratories | $1,596.52 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Cvrx, INC. | $272.88 | 2019-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $208.20 | 2019-2025 | |
| Bridgebio Pharma, INC. | $200.03 | 2025 | Attruby |
| United Therapeutics Corporation | $181.96 | 2024-2025 | Tyvaso, Remodulin, Orenitram |
| Abiomed | $174.15 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.98 | 2019-2023 | Lifevest |
| Boston Scientific Corporation | $80.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $67.67 | 2022-2025 | Camzyos |
| Medtronic, INC. | $39.93 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.91 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $38.25 | 2023 | Uptravi, Opsumit |
| Medtronic Vascular, INC. | $20.37 | 2019 | |
| Scpharmaceuticals INC. | $19.99 | 2023 | |
| Amgen INC. | $19.44 | 2019 | |
| Daiichi Sankyo INC. | $18.51 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $16.07 | 2022 | |
| Cardiva Medical, INC. | $13.29 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Varian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.